We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Arrowhead Prices $36 Million Private Offering

News   May 01, 2013

 
Arrowhead Prices $36 Million Private Offering
 
 
Advertisement
 

RELATED ARTICLES

Russia’s COVID-19 Vaccine “Approved for Mass Production” Despite No Phase III Data

News

The scientific community has been left somewhat perplexed today after Russian President Vladamir Putin announced that Russian authorities have approved the world's first COVID-19 vaccine.

READ MORE

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

Circulating DNA From Tumor Could Predict Immunotherapy Outcome

News

A newly developed test that detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, according to researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE